Pfizer Inc. $PFE Shares Bought by Capital Advisors Inc. OK

Capital Advisors Inc. OK boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 6.9% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,640,726 shares of the biopharmaceutical company’s stock after purchasing an additional 105,365 shares during the period. Capital Advisors Inc. OK’s holdings in Pfizer were worth $40,854,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Fiduciary Alliance LLC lifted its holdings in Pfizer by 46.4% in the third quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock valued at $3,701,000 after acquiring an additional 46,043 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in shares of Pfizer during the 3rd quarter worth approximately $3,019,000. Vista Investment Partners LLC increased its holdings in shares of Pfizer by 236.1% during the 3rd quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock valued at $1,774,000 after purchasing an additional 48,900 shares in the last quarter. Money Concepts Capital Corp grew its position in Pfizer by 29.9% during the third quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock valued at $6,325,000 after buying an additional 57,188 shares during the period. Finally, Kepler Cheuvreux Suisse SA acquired a new stake in Pfizer during the third quarter valued at $16,613,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on PFE shares. Citigroup started coverage on shares of Pfizer in a research report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price objective for the company. Bank of America cut their price target on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. Zacks Research raised Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a report on Wednesday, February 4th. Finally, Barclays assumed coverage on Pfizer in a research report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $28.19.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Fresh real‑world data from Pfizer’s Swedish observational study on Ibrance (palbociclib) is being framed as a positive signal for the drug’s real‑world effectiveness and market durability, which could support oncology revenue expectations. Pfizer’s Swedish Ibrance Study
• Positive Sentiment: Heightened media and retail investor attention around Pfizer’s GLP‑1/weight‑loss pipeline (including coverage noting share strength despite a high‑profile “pass” comment) is boosting sentiment—investors are pricing potential upside from a once‑monthly treatment. Pfizer’s (PFE) Shares Up Since Jim Cramer Said “Pass”
• Positive Sentiment: Dividend appeal remains a tailwind for income investors—Pfizer is regularly cited among large caps with attractive dividends, supporting buy‑and‑hold interest. Pfizer – Among the 15 Large Cap Stocks with Highest Dividends
• Neutral Sentiment: Retail and institutional attention is elevated (high search/coverage), which can amplify moves but doesn’t guarantee direction — monitor whether flow sustains. Investors Heavily Search Pfizer Inc. (PFE)
• Neutral Sentiment: Broader sector moves (e.g., large deals and AI partnerships at peers) are reshaping investor rotation in healthcare but are not direct Pfizer catalysts; they do, however, affect relative valuation dynamics. Eli Lilly Ramps Up AI Ambitions
• Negative Sentiment: Fundamentals still carry risk: quarterly revenue was slightly down year‑over‑year even as EPS beat estimates, and Pfizer faces stiff competition in the GLP‑1/weight‑loss space from larger early movers—both could cap upside if execution or pricing weakens.

Pfizer Stock Up 1.1%

Shares of NYSE PFE opened at $28.08 on Wednesday. The firm has a market cap of $159.67 billion, a price-to-earnings ratio of 20.65 and a beta of 0.47. The company’s 50-day simple moving average is $26.94 and its 200-day simple moving average is $25.75. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $28.31.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.63 EPS. Equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.